Sheets Smith Wealth Management lowered its stake in Eli Lilly and Company (NYSE:LLY) by 14.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,253 shares of the company’s stock after selling 549 shares during the period. Sheets Smith Wealth Management’s holdings in Eli Lilly and were worth $268,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. First Command Financial Services Inc. raised its position in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares during the last quarter. Heritage Trust Co bought a new position in shares of Eli Lilly and during the first quarter valued at $135,000. Point72 Asia Hong Kong Ltd raised its position in shares of Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares during the last quarter. Penserra Capital Management LLC raised its position in shares of Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after buying an additional 176 shares during the last quarter. Finally, American National Bank raised its position in shares of Eli Lilly and by 5.2% in the second quarter. American National Bank now owns 2,088 shares of the company’s stock valued at $172,000 after buying an additional 104 shares during the last quarter. 75.59% of the stock is currently owned by institutional investors.
Shares of Eli Lilly and Company (NYSE LLY) opened at 77.07 on Friday. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The stock’s 50 day moving average is $82.39 and its 200-day moving average is $81.90. The firm has a market cap of $81.31 billion, a P/E ratio of 33.35 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the prior year, the firm posted $0.86 earnings per share. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. Equities analysts anticipate that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.70%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.
TRADEMARK VIOLATION WARNING: This report was published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.com-unik.info/2017/08/19/eli-lilly-and-company-nyselly-stake-reduced-by-sheets-smith-wealth-management-updated-updated.html.
Several brokerages have recently weighed in on LLY. BMO Capital Markets reiterated a “sell” rating and set a $73.00 price objective on shares of Eli Lilly and in a report on Friday, August 4th. Berenberg Bank reiterated a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a report on Friday, August 4th. TheStreet upgraded shares of Eli Lilly and from a “c+” rating to a “b+” rating in a report on Tuesday, July 25th. Leerink Swann lowered shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $93.00 to $90.00 in a report on Wednesday, July 26th. Finally, BidaskClub upgraded shares of Eli Lilly and from a “sell” rating to a “hold” rating in a report on Wednesday, June 14th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the stock. Eli Lilly and has an average rating of “Hold” and an average price target of $88.27.
In other Eli Lilly and news, VP Michael J. Harrington sold 22,833 shares of the stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $79.97, for a total value of $1,825,955.01. Following the transaction, the vice president now owns 62,056 shares of the company’s stock, valued at $4,962,618.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of the stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $83.05, for a total value of $17,855,750.00. Following the completion of the transaction, the insider now directly owns 124,475,804 shares in the company, valued at approximately $10,337,715,522.20. The disclosure for this sale can be found here. Insiders have sold 669,733 shares of company stock worth $55,845,287 in the last ninety days. 0.20% of the stock is currently owned by insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.